| Filed On | Filing |
|---|---|
| 10 Nov 2026 | SCHEDULE 13G |
| 05 Nov 2026 |
Form 4: Paterson Dan, Director
Sold 1,299 shares ($12.5K) |
| 05 Nov 2026 | S-3ASR |
| 05 Nov 2026 | FORM S-8 |
| 05 Nov 2026 |
8-K: Regulation FD Disclosure
Delivering Novel Therapies for RAS/MAPK Pathway - Driven Cancers CORPORATE PRESENTATION NOVEMBER 2026 |
| 05 Nov 2026 | 10-Q |
| 30 Oct 2026 | SCHEDULE 13G/A |
| 14 Oct 2026 |
8-K: Other Events
Introductory. Verastem, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i) an aggregate of 30,937,500 shares (the “Shares”) of its common stoc... |
| 14 Oct 2026 | 424B5 |
| 14 Oct 2026 | 424B5 |
| 14 Oct 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +2 more
VS - 7375 : Potential Best - in - Class KRAS G12D (ON/OFF) Inhibitor R&D Update October 14, 2026 |
| 02 Oct 2026 |
Form 4: Paterson Dan, Director
Disposed of 106,893 shares (Grant/Award Acquisition) · Sold 44,121 shares ($353K) |
| 02 Oct 2026 |
Form 4: Calkins Daniel, Chief Financial Officer
Disposed of 8,333 shares (Grant/Award Acquisition) · Sold 2,566 shares ($20.5K) |
| 01 Oct 2026 | 144 |
| 23 Sep 2026 |
Form 4: Calkins Daniel, Chief Financial Officer
Sold 55 shares ($424) |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 07 Aug 2026 | SCHEDULE 13G |
| 06 Aug 2026 |
8-K: Results of Operations and Financial Condition
AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million |
| 06 Aug 2026 | 10-Q |
| 07 Aug 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
This Amendment No. 3 to Note Purchase Agreement (this “Amendment”), dated as of the date first set forth above, is entered into by and among Verastem, Inc., a Delaware corporation (“Issuer”), the Persons listed on the signature pages her... |
Loading...